Literature DB >> 8640984

Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist.

S Kaddoura1, J D Firth, K R Boheler, P H Sugden, P A Poole-Wilson.   

Abstract

BACKGROUND: Endothelin-1 (ET-1) has potent effects on cell growth and induces hypertrophy of cultured ventricular myocytes. Catecholamines increase expression of ET-1 mRNA by cultured myocytes. We investigated the role of endogenous ET-1 in catecholamine-induced hypertrophy in vivo by studying the effects of continuous norepinephrine infusion on physical and molecular markers of ventricular hypertrophy, ventricular and noncardiac expression of ET-1 mRNA, and the acute effects of bosentan, an orally active ETA and ETB receptor antagonist. METHODS AND
RESULTS: Seventy male Sprague-Dawley rats (175 to 200 g) were divided into four groups: (1) sham-operated rats, (2) norepinephrine-infused rats (600 micrograms.kg-1.h-1 by subcutaneous osmotic pump, up to 7 days), (3) sham-operated rats given bosentan, and (4) norepinephrine-infused rats given bosentan. Bosentan (100 mg/kg once daily) was administered by gavage for 6 days starting 1 day before operation. Norepinephrine caused increases in absolute ventricular weight and ratios of ventricular weight to body weight and ventricular RNA to protein. Ventricular expression of mRNAs for atrial natriuretic factor, skeletal alpha-actin, and beta-myosin heavy chain, which in adult rat ventricle are indicators of hypertrophy, also increased. Ventricular expression of ET-1 mRNA was elevated in the norepinephrine group at 1, 2, and 3 days. By 5 days, this had fallen to control levels. In lung, kidney, and skeletal muscle, norepinephrine did not significantly increase expression of ET-1 mRNA. Bosentan attenuated norepinephrine-induced increases in ventricular weight, ratio of RNA to protein, and expression of skeletal alpha-actin mRNA and beta-myosin heavy chain mRNA at 5 days, but it did not attenuate increased ventricular expression of atrial natriuretic factor mRNA.
CONCLUSIONS: These data suggest that endogenous ET-1 plays a direct role in mediating norepinephrine-induced ventricular hypertrophy in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640984     DOI: 10.1161/01.cir.93.11.2068

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

1.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 2.  Endothelins: pathophysiology and treatment implications in chronic heart failure.

Authors:  John R Teerlink
Journal:  Curr Heart Fail Rep       Date:  2005-12

3.  The role of the neurohormonal system in heart failure.

Authors:  M Komajda; F Pousset; R Isnard; P Lechat
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

4.  Role of endogenous endothelin in the regulation of basal coronary tone in the rat.

Authors:  A T Goodwin; M Amrani; C C Gray; J Jayakumar; M H Yacoub
Journal:  J Physiol       Date:  1998-09-01       Impact factor: 5.182

Review 5.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Plasma C-terminal pro-endothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension.

Authors:  M A Al-Omari; M Khaleghi; T H Mosley; N G Morgenthaler; J Struck; A Bergmann; I J Kullo
Journal:  J Hum Hypertens       Date:  2010-02-25       Impact factor: 3.012

Review 7.  Endothelin and its antagonists in hypertension: can we foresee the future?

Authors:  P Moreau; T J Rabelink
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 8.  Endothelin in heart failure.

Authors:  G Sütsch; M Barton
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 9.  The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction.

Authors:  Elizabeth A W Chan; Barbara Buckley; Aimen K Farraj; Leslie C Thompson
Journal:  Pharmacol Ther       Date:  2016-05-21       Impact factor: 12.310

10.  Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.

Authors:  Se Min Ryu; Hark Jei Kim; Kyu Ran Cho; Won-Min Jo
Journal:  J Korean Med Sci       Date:  2009-09-23       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.